These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

616 related items for PubMed ID: 28002268

  • 1. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Sakurada Y, Sugiyama A, Tanabe N, Kikushima W, Kume A, Iijima H.
    Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
    [Abstract] [Full Text] [Related]

  • 2. Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy.
    Yoneda A, Wakiyama H, Kurihara J, Kitaoka T.
    Eur J Ophthalmol; 2020 Nov; 30(6):1473-1479. PubMed ID: 31476891
    [Abstract] [Full Text] [Related]

  • 3. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, Kusuhara S, Nakamura M.
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
    [Abstract] [Full Text] [Related]

  • 4. Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy.
    Takayama K, Kaneko H, Kataoka K, Ueno S, Chang-Hua P, Ito Y, Terasaki H.
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):449-455. PubMed ID: 27538907
    [Abstract] [Full Text] [Related]

  • 5. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
    Ricci F, Calabrese A, Regine F, Missiroli F, Ciardella AP.
    Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
    [Abstract] [Full Text] [Related]

  • 6. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
    Saito M, Kano M, Itagaki K, Ise S, Imaizumi K, Sekiryu T.
    Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
    [Abstract] [Full Text] [Related]

  • 7. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
    Morimoto M, Matsumoto H, Mimura K, Akiyama H.
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
    [Abstract] [Full Text] [Related]

  • 8. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy.
    Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Kume A, Iijima H.
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):311-316. PubMed ID: 27534663
    [Abstract] [Full Text] [Related]

  • 9. Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
    Saito M, Iida T, Kano M.
    Retina; 2012 Jul; 32(7):1272-9. PubMed ID: 22547209
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
    Lai K, Li Y, Zhou L, Zhong X, Huang C, Xu F, Lu L, Ge J, Jin C.
    BMC Ophthalmol; 2018 Jun 20; 18(1):144. PubMed ID: 29925341
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
    Lee JE, Shin JP, Kim HW, Chang W, Kim YC, Lee SJ, Chung IY, Lee JE, VAULT study group.
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar 20; 255(3):493-502. PubMed ID: 27628062
    [Abstract] [Full Text] [Related]

  • 16. REDUCED VASCULAR DENSITY IN THE CHOROID AFTER TREATMENT WITH PHOTODYNAMIC THERAPY COMBINED WITH AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Mukai R, Matsumoto H, Miyakubo T, Akiyama H.
    Retina; 2021 Jan 01; 41(1):156-161. PubMed ID: 32251239
    [Abstract] [Full Text] [Related]

  • 17. The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Nakai S, Matsumiya W, Keiko O, Miki A, Nakamura M, Honda S.
    Jpn J Ophthalmol; 2019 Jan 01; 63(1):100-108. PubMed ID: 30406511
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Feller C, Margaron P, Lim TH, Lee WK, EVEREST II study group.
    JAMA Ophthalmol; 2017 Nov 01; 135(11):1206-1213. PubMed ID: 28983556
    [Abstract] [Full Text] [Related]

  • 20. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
    Chaikitmongkol V, Upaphong P, Patikulsila D, Jirarattanasopa P, Choovuthayakorn J, Watanachai N, Kunavisarut P, Ratanasukon M, Bhurayanontachai P, Ingviya T, Bressler SB, Bressler NM.
    Ophthalmol Retina; 2022 Jan 01; 6(1):21-28. PubMed ID: 33781929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.